220 related articles for article (PubMed ID: 34673001)
61. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
62. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
Rathi E; Kumar A; Kini SG
J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
[TBL] [Abstract][Full Text] [Related]
63. PD-1-Targeted Discovery of Peptide Inhibitors by Virtual Screening, Molecular Dynamics Simulation, and Surface Plasmon Resonance.
Wang Y; Guo H; Feng Z; Wang S; Wang Y; He Q; Li G; Lin W; Xie XQ; Lin Z
Molecules; 2019 Oct; 24(20):. PubMed ID: 31640203
[TBL] [Abstract][Full Text] [Related]
64. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules.
Yang J; Hu L
Med Res Rev; 2019 Jan; 39(1):265-301. PubMed ID: 30215856
[TBL] [Abstract][Full Text] [Related]
65. Competition NMR for Detection of Hit/Lead Inhibitors of Protein-Protein Interactions.
Musielak B; Janczyk W; Rodriguez I; Plewka J; Sala D; Magiera-Mularz K; Holak T
Molecules; 2020 Jul; 25(13):. PubMed ID: 32630327
[TBL] [Abstract][Full Text] [Related]
66. In silico screening and surface plasma resonance-based verification of programmed death 1-targeted peptides.
Zhang P; Li C; Ji X; Gao M; Lyu S; Dai X; Du J
Chem Biol Drug Des; 2020 Mar; 95(3):332-342. PubMed ID: 31755641
[TBL] [Abstract][Full Text] [Related]
67. Bioactive compounds derived from marine source: a potential immunotherapy treatment.
Jabeen Y; Yousaf N; Sarjadi MS; Gansau JA; Goh LPW
J Biomol Struct Dyn; 2024 Jul; 42(11):5657-5668. PubMed ID: 37387587
[TBL] [Abstract][Full Text] [Related]
68. A combined approach of structure-based virtual screening and NMR to interrupt the PD-1/PD-L1 axis: Biphenyl-benzimidazole containing compounds as novel PD-L1 inhibitors.
Donati G; Viviano M; D'Amore VM; Cipriano A; Diakogiannaki I; Amato J; Tomassi S; Brancaccio D; Russomanno P; Di Leva FS; Arosio D; Seneci P; Taliani S; Magiera-Mularz K; Musielak B; Skalniak L; Holak TA; Castellano S; La Pietra V; Marinelli L
Arch Pharm (Weinheim); 2024 Mar; 357(3):e2300583. PubMed ID: 38110703
[TBL] [Abstract][Full Text] [Related]
69. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1.
Cheng B; Ren Y; Cao H; Chen J
Eur J Med Chem; 2020 Aug; 199():112377. PubMed ID: 32388281
[TBL] [Abstract][Full Text] [Related]
70. Computational analysis of PD-L1 dimerization mechanism induced by small molecules and potential dynamical properties.
Xu X; Luo S; Zhao X; Tang B; Zhang E; Liu J; Duan L
Int J Biol Macromol; 2024 Apr; 265(Pt 1):130921. PubMed ID: 38492688
[TBL] [Abstract][Full Text] [Related]
71. N-glycosylation and ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: A molecular modeling study.
Bailly C; Vergoten G
Comput Biol Chem; 2020 Oct; 88():107362. PubMed ID: 32871472
[TBL] [Abstract][Full Text] [Related]
72. The Stone Guest: How Does pH Affect Binding Properties of PD-1/PD-L1 Inhibitors?
Riccio A; Coletti A; Dolciami D; Mammoli A; Cerra B; Moretti S; Gioiello A; Ferlin S; Puxeddu E; Macchiarulo A
ChemMedChem; 2021 Feb; 16(3):568-577. PubMed ID: 33085193
[TBL] [Abstract][Full Text] [Related]
73. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
74. Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.
Zhou K; Lu J; Yin X; Xu H; Li L; Ma B
Biophys Chem; 2019 Oct; 253():106213. PubMed ID: 31276987
[TBL] [Abstract][Full Text] [Related]
75. Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding.
Akiyama Y; Ashizawa T; Iizuka A; Ando T; Ishikawa Y; Kondou R; Miyata H; Maeda C; Kanematsu A; Sugino T; Yamaguchi K
Anticancer Res; 2022 Nov; 42(11):5233-5247. PubMed ID: 36288869
[TBL] [Abstract][Full Text] [Related]
76. Unravelling novel congeners from acetyllysine mimicking ligand targeting a lysine acetyltransferase PCAF bromodomain.
Suryanarayanan V; Singh SK
J Biomol Struct Dyn; 2018 Dec; 36(16):4303-4319. PubMed ID: 29228881
[TBL] [Abstract][Full Text] [Related]
77. Design and evaluation of α-helix-based peptide inhibitors for blocking PD-1/PD-L1 interaction.
Rui M; Zhang W; Mi K; Ni H; Ji W; Yu X; Qin J; Feng C
Int J Biol Macromol; 2023 Dec; 253(Pt 2):126811. PubMed ID: 37690647
[TBL] [Abstract][Full Text] [Related]
78. Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors.
Almahmoud S; Zhong HA
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546905
[TBL] [Abstract][Full Text] [Related]
79. Screening of kinase inhibitors downregulating PD-L1 expression via on/in cell quantitative immunoblots.
Xie Y; Ding J; Cui X; Wu M; Huang C; Zhang R; Wang J; Li X; Cen S; Zhou J
Eur J Pharm Sci; 2020 Jan; 142():105088. PubMed ID: 31626963
[TBL] [Abstract][Full Text] [Related]
80. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
Zak KM; Kitel R; Przetocka S; Golik P; Guzik K; Musielak B; Dömling A; Dubin G; Holak TA
Structure; 2015 Dec; 23(12):2341-2348. PubMed ID: 26602187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
